The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
November 15, 2022
The Board of Nursing extends best wishes to our advanced practice licensees during Nurse Practitioner Week and appreciates your dedication in helping to meet the health care needs of Floridians and visitors to our state. Click here to view the signed proclamation … Continue reading
November 8, 2022
The latest issue of the Florida Nursing Quarterly is now available. Click here to view the full issue. Continue reading